Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

Delayed Quote. Delayed  - 07/27 07:11:52 pm
11.96 USD   +3.73%
07/20 Sucampo Announces Second Quarter 2016 Earnings Call
07/11 SUCAMPO PHARMAC : Provides Update on Cobiprostone Development Progra..
07/08 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at ..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/21/2016 07/22/2016 07/25/2016 07/26/2016 07/27/2016 Date
11.61(c) 11.41(c) 11.37(c) 11.53(c) 11.96 Last
300 728 292 537 206 461 234 579 96 673 Volume
+0.09% -1.72% -0.35% +1.41% +3.73% Change
More quotes
Financials ($)
Sales 2016 203 M
EBIT 2016 83,6 M
Net income 2016 31,7 M
Debt 2016 141 M
Yield 2016 -
Sales 2017 227 M
EBIT 2017 106 M
Net income 2017 63,4 M
Debt 2017 87,2 M
Yield 2017 -
P/E ratio 2016 15,79
P/E ratio 2017 8,09
EV / Sales2016 3,29x
EV / Sales2017 2,71x
Capitalization 528 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia.It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
07/20 Sucampo Announces Second Quarter 2016 Earnings Call
07/12 SUCAMPO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements a..
07/11 SUCAMPO PHARMACEUTICALS : Financial Statements and Exhibits (form 8-K/A)
07/11 SUCAMPO PHARMACEUTICALS : Provides Update on Cobiprostone Development Program
07/08 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at Cantor Fitzg..
06/28 SUCAMPO PHARMACEUTICALS : Completion of Acquisition or Disposition of Assets, Fi..
06/08 SUCAMPO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Hold..
05/31 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferie..
05/18 SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the 2016 UBS ..
05/17 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2016 UBS..
More news
Sector news : Bio Therapeutic Drugs
01:22p GSK chases next biotech asthma drug with 175 million pounds J&J deal
07/26 GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJCELGENE : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
2015The bullish trend is not over
More Strategies
News from SeekingAlpha
07/22 What To Do With Your Relypsa Winnings
07/21 This Impressive Small-Cap Pharma Is Set For Its Next Big Move
05/28 LANNETT : Structural Benefits Of The Kremers Acquisition: 100+% Upside
05/04 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q1 2016 Results - Earn..
05/04 Sucampo beats by $0.02, beats on revenue
Advertisement
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Technical analysis trends SUCAMPO PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 20,7 $
Spread / Average Target 79%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Daniel P. Getman Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICAL..-33.31%528
AMGEN, INC.3.29%125 957
GILEAD SCIENCES, INC.-19.90%107 944
CELGENE CORPORATION-11.34%82 247
REGENERON PHARMACEUTIC..-27.26%41 850
VERTEX PHARMACEUTICALS..-24.52%23 493
More Results